6/7/2025

Janusmed sex and gender

Janusmed sex and gender – alirocumab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Alirocumab

Alirocumab

Class : C

Show all info

Print

Contact us

  1. Praluent (alirocumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-12-05, cited 2020-05-25]

  2. Vallejo-Vaz AJ , Ginsberg HN, Davidson MH, Eckel RH , Cannon CP , Lee LV, Bessac L, Pordy R, Letierce A, Ray KK. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018;7(18):e009221.

  3. Nicolas X, Djebli N, Rauch C, Brunet A, Hurbin F, Martinez JM et al. Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II. Clin Pharmacokinet. 2019;58(1):115-130.

  4. Gürgöze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience. Clin Pharmacol Ther. 2019;105(2):496-504.

  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Praluent (alirocumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-12-05, cited 2020-05-25]
  2. Vallejo-Vaz AJ , Ginsberg HN, Davidson MH, Eckel RH , Cannon CP , Lee LV, Bessac L, Pordy R, Letierce A, Ray KK. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018;7(18):e009221.
  3. Nicolas X, Djebli N, Rauch C, Brunet A, Hurbin F, Martinez JM et al. Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II. Clin Pharmacokinet. 2019;58(1):115-130.
  4. Gürgöze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience. Clin Pharmacol Ther. 2019;105(2):496-504.
  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]